This inventor holds 2 USPTO granted patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: Innovations of Yon-Neng Wu
Introduction
Yon-Neng Wu is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of recombinant proteins with therapeutic applications. With a total of 2 patents, his work focuses on advancing cancer and antiviral treatments.
Latest Patents
Wu's latest patents include a mutant form of a cytotoxic ribonucleolytic protein that allows for production by recombinant methods. This invention provides recombinant Onc (rOnc) compositions and methods. The recombinant Onc proteins feature an amino terminal methionine, which facilitates production in bacterial host cells. Cleaving the amino terminal methionine reveals the amino terminal glutamine of the polypeptide, which is crucial for its function. The cyclization of this amino terminal glutamine to a pyroglutamyl residue results in rOnc polypeptides and proteins that exhibit anti-cancer and anti-viral activity.
Career Highlights
Yon-Neng Wu is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution underscores his commitment to advancing medical science and improving patient outcomes through innovative research.
Collaborations
Some of his notable coworkers include Richard J. Youle and Veena M. Vasandani. Their collaborative efforts contribute to the ongoing research and development in the field of biotechnology.
Conclusion
Yon-Neng Wu's contributions to the field of biotechnology through his patents and research at the National Institutes of Health highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer and antiviral therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile